PML nuclear bodies: Assembly and oxidative stress-sensitive sumoylation

Nucleus

Volumn 5, Issue 6, 2014, Pages 499-507

  Sahin, Umut ^a,b   De Thé, Hugues ^a,b,c,d   Lallemand Breitenbach, Valérie ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Universitaire d'Hématologie   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d l'alimentation et l'Environnement   (France)

Author keywords

Arsenic; Degradation; Interferon; Nuclear bodies; Oxidative stress; PML; Post translational modifications; RNF4; Senescence; SIM; SUMO

Indexed keywords

ATAXIN 1; DNA REPAIR PROTEIN; INTERFERON; NUCLEIC ACID BINDING PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; REACTIVE OXYGEN METABOLITE; SUMO PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; NUCLEAR PROTEIN; REPRESSOR PROTEIN; RNF4 PROTEIN, HUMAN; SIM1 PROTEIN, HUMAN; SUMO 1 PROTEIN;

BIOGENESIS; CELL NUCLEUS INCLUSION BODY; CELLULAR DISTRIBUTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; OLIGOMERIZATION; ONCOGENE; OXIDATIVE STRESS; PROMYELOCYTIC LEUKEMIA; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW; SPINOCEREBELLAR DEGENERATION; SUMOYLATION; UBIQUITINATION; CELL AGING; CELL NUCLEUS; GENETICS; METABOLISM;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL AGING; CELL NUCLEUS; HUMANS; INTRANUCLEAR INCLUSION BODIES; NUCLEAR PROTEINS; OXIDATIVE STRESS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; REPRESSOR PROTEINS; SUMO-1 PROTEIN; SUMOYLATION; TRANSCRIPTION FACTORS;

EID: 84921901572     PISSN: 19491034     EISSN: 19491042     Source Type: Journal    
DOI: 10.4161/19491034.2014.970104     Document Type: Review

References (137)

1. Sexton T, Schober H, Fraser P, Gasser SM. Gene regulation through nuclear organization. Nat Struct Mol Biol 2007; 14:1049-55; PMID:17984967; http://dx.doi.org/10.1038/nsmb1324
2. Mao YS, Zhang B, Spector DL. Biogenesis and function of nuclear bodies. Trends Genet 2011; 27:295-306; PMID:21680045; http://dx.doi.org/10.1016/j.tig.2011.05.006
3. Rajendra TK, Praveen K, Matera AG. Genetic analysis of nuclear bodies: from nondeterministic chaos to deterministic order. Cold Spring Harb Symp Quant Biol 2010; 75:365-74; PMID:21467138; http://dx.doi.org/10.1101/sqb.2010.75.043
4. Dundr M. Nuclear bodies: multifunctional companions of the genome. Curr Opin Cell Biol 2012; 24:415-22; PMID:22541757; http://dx.doi.org/10.1016/j.ceb.2012.03.010
5. Zaidi SK, Young DW, Javed A, Pratap J, Montecino M, van Wijnen A, et al. Nuclear microenvironments in biological control and cancer. Nat Rev Cancer 2007; 7:454-63; PMID:17522714; http://dx.doi.org/10.1038/nrc2149
6. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat RevMolCellBiol2007; 8:1006-16; PMID:17928811; http://dx.doi.org/10.1038/nrm2277
7. Lallemand-Breitenbach V, de The H. PML nuclear bodies. Cold Spring Harb Perspect Biol 2010; 2: a000661; PMID:20452955; http://dx.doi.org/10.1101/cshperspect.a000661
8. Szostecki C, Guldner HH, Will H. Autoantibodies against "nuclear dots" in primary biliary cirrhosis. Semin Liver Dis 1997; 17:71-8; PMID:9089912; http://dx.doi.org/10.1055/s-2007-1007184
9. Daniel M-T, Koken M, Romagnee O, Barbey S, Bazar-bachi A, Stadler M, Guillemin MC, Degos L, Chomi-enne C, de Thee H. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 1993; 82:1858-67; PMID:8400236
10. de The H, Le Bras M, Lallemand-Breitenbach V. The cell biology of disease: acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol 2012; 198:11-21; PMID:22778276; http://dx.doi.org/10.1083/jcb.201112044.
11. de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010; 10:775-83; PMID:20966922; http://dx.doi.org/10.1038/nrc2943
12. de Thee H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347:558-61; PMID:2170850; http://dx.doi.org/10.1038/347558a0
13. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, Grignani F, Pelicci PG. Structure and origin of the acute promyelocytic leukemia myl/RARa cDNA and characterization of its retinol-binding and transactivation properties. Oncogene 1991; 6:1285-92; PMID:1650447
14. de Thee H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66:675-84; PMID:1652369; http://dx.doi.org/10.1016/0092-8674(91)90113-D
15. Dos Santos GA, Kats L, Pandolfi PP. Synergy against PML-RARa: targeting transcription, prote-olysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med 2013; 210:2793-802; PMID:24344243; http://dx.doi.org/10.1084/jem.20131121
16. Melnick A, Licht JD. Deconstructing a disease: RAR-alpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93:3167-215; PMID:10233871
17. Insinga A, Monestiroli S, Ronzoni S, Carbone R, Pearson M, Pruneri G, Viale G, Appella E, Pelicci P, Minucci S. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J 2004; 23:1144-54; PMID:14976551; http://dx.doi.org/10.1038/sj.emboj.7600109
18. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell 2002; 108:165-70; PMID:11832207; http://dx.doi.org/10.1016/S0092-8674(02)00626-8
19. de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G, Lowe SW. PML is a direct p53 target that modulates p53 effector functions. Mol Cell 2004; 13:523-35; PMID:14992722; http://dx.doi.org/10.1016/S1097-2765(04)00062-0
20. Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP, Haupt Y. The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem 2003; 278:33134-41; PMID:12810724; http://dx.doi.org/10.1074/jbc.M301264200
21. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C, Del Sal G. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J 2000; 19:6185-95; PMID:11080164; http://dx.doi.org/10.1093/emboj/19.22.6185
22. Pearson M, Pelicci PG. PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene 2001; 20:7250-6; PMID:11704853; http://dx.doi.org/10.1038/sj.onc.1204856
23. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Min-ucci S, Pandolfi PP, et al. PML regulates p53 acetyla-tion and premature senescence induced by oncogenic Ras. Nature 2000; 406:207-10; PMID:10910364; http://dx.doi.org/10.1038/35021000
24. Ablain J, Rice K, Soilihi H, de Reynies A, Minucci S, de Thee H. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat Med 2014; 20:167-74; PMID:24412926; http://dx.doi.org/10.1038/nm.3441
25. Maul GG, Yu E, Ishov AM, Epstein AL. Nuclear domain 10 (ND10) associated proteins are also present in nuclear bodies and redistribute to hundreds of nuclear sites after stress. J Cell Biochem 1995; 59:498-513; PMID:8749719; http://dx.doi.org/10.1002/jcb.240590410
26. Sahin U, Ferhi O, Jeanne M, Benhenda S, Berthier C, Jollivet F, Niwa-Kawakita M, Faklaris O, Setterblad N, de Thee H. Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins. J Cell Biol 2014; 204:931-45; PMID:24637324; http://dx.doi.org/10.1083/jcb.201305148
27. Dellaire G, Bazett-Jones DP. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 2004; 26:963-77; PMID:15351967; http://dx.doi.org/10.1002/bies.20089
28. Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honore N, Doubeikovsky A, Duprez E, Pandolfi PP, Puvion E, Freemont P, et al. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As(2)O(3)-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 2001; 193:1361-72; PMID:11413191; http://dx.doi.org/10.1084/jem.193.12.1361
29. Luciani JJ, Depetris D, Usson Y, Metzler-Guillemain C, Mignon-Ravix C, Mitchell MJ, Megarbane A, Sarda P, Sirma H, Moncla A, et al. PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase. J CellSci2006; 119:2518-31; PMID:16735446; http://dx.doi.org/10.1242/jcs.02965
30. Lang M, Jegou T, Chung I, Richter K, Munch S, Udvarhelyi A, Cremer C, Hemmerich P, Engelhardt J, Hell SW, et al. Three-dimensional organization of promyelocytic leukemia nuclear bodies. J Cell Sci 2010; 123:392-400; PMID:20130140; http://dx.doi.org/10.1242/jcs.053496
31. Razin SV, Iarovaia OV, Vassetzky YS. A requiem to the nuclear matrix: from a controversial concept to 3D organization of the nucleus. Chromosoma 2014; 123:217-24; PMID:24664318; http://dx.doi.org/10.1007/s00412-014-0459-8
32. Stuurman N, Meijne AML, van der Pol AJ, de Jong L, van Driel R, van Renswoude J. The nuclear matrix from cells of different origin. Evidence for a common set of matrix proteins. J Biol Chem 1990; 265:5460-5; PMID:2180926
33. Bischof O, Kirsh O, Pearson M, Itahana K, Pelicci PG, Dejean A. Deconstructing PML-induced premature senescence. EMBO J 2002; 21:3358-69; PMID:12093737; http://dx.doi.org/10.1093/emboj/cdf341
34. Rokudai S, Laptenko O, Arnal SM, Taya Y, Kitabaya-shi I, Prives C. MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc Natl Acad Sci U S A 2013; 110:3895-900; PMID:23431171; http://dx.doi.org/10.1073/pnas.1300490110
35. Mazza M, Pelicci PG. Is PML a tumor suppressor? Front Oncol 2013; 3:174; PMID:23847764; http://dx.doi.org/10.3389/fonc.2013.00174
36. Bernardi R, Pandolfi PP. A dialog on the first 20 years of PML research and the next 20 ahead. Front Oncol 2014; 4:23; PMID:24575390; http://dx.doi.org/10.3389/fonc.2014.00023
37. Chung I, Osterwald S, Deeg KI, Rippe K. PML body meets telomere: the beginning of an ALTernate ending? Nucleus 2012; 3:263-75; PMID:22572954; http://dx.doi.org/10.4161/nucl.20326
38. Wang Z-G, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP. PML is essential for multiple apoptotic pathways. Nat Genet 1998; 20:266-72; PMID:9806545; http://dx.doi.org/10.1038/3030
39. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss JF, Maul GG. PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 1999; 147:221-34; PMID:10525530; http://dx.doi.org/10.1083/jcb.147.2.221
40. Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, Janin A, de Thee H. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res 2006; 66:6192-8; PMID:16778193; http://dx.doi.org/10.1158/0008-5472.CAN-05-3792
41. Weidtkamp-Peters S, Lenser T, Negorev D, Gerstner N, Hofmann TG, Schwanitz G, Hoischen C, Maul G, Dittrich P, Hemmerich P. Dynamics of component exchange at PML nuclear bodies. J Cell Sci 2008; 121:2731-43; PMID:18664490; http://dx.doi.org/10.1242/jcs.031922
42. Kaufmann SH, Brunet G, Talbot B, Lamarr D, Dumas C, Shaper JH, Poirier G. Association of poly(ADP-ribose) polymerase with the nuclear matrix: the role of intermolecular disulfide bond formation, RNA retention, and cell type. Exp Cell Res 1991; 192:524-35; PMID:1703086; http://dx.doi.org/10.1016/0014-4827(91)90072-3
43. Humphrey GW, Pigiet V. Protein disulfide crosslink-ing stabilizes a polyoma large T antigen-host protein complex on the nuclear matrix. Exp Cell Res 1987; 171:122-36; PMID:3040447; http://dx.doi.org/10.1016/0014-4827(87)90256-4
44. Stuurman N, Floore A, Colen A, de Jong L, van Driel R. Stabilization of the nuclear matrix by disulfide bridges: identification of matrix polypeptides that form disulfides. Exp Cell Res 1992; 200:285-94; PMID:1572396; http://dx.doi.org/10.1016/0014-4827(92)90174-7
45. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, et al. The tripartite motif family identifies cell compartments. EMBO J2001; 20:2140-51; PMID:11331580; http://dx.doi.org/10.1093/emboj/20.9.2140
46. Meroni G, Diez-Roux G. TRIM/RBCC, a novel class of 'single protein RING finger' E3 ubiquitin ligases. Bioessays 2005; 27:1147-57; PMID:16237670; http://dx.doi.org/10.1002/bies.20304
47. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, Peres L, Berthier C, Soilihi H, Raught B, et al. PML/RARAoxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 2010; 18:88-98; PMID:20609355; http://dx.doi.org/10.1016/j.ccr.2010.06.003
48. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010; 328:240-3; PMID:20378816; http://dx.doi.org/10.1126/science.1183424
49. Hay RT. Decoding the SUMO signal. Biochem Soc Trans 2013; 41:463-73; PMID:23514139; http://dx.doi.org/10.1042/BST20130015
50. Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 2010; 11:861-71; PMID:21102611; http://dx.doi.org/10.1038/nrm3011
51. Cubenas-Potts C, Matunis MJ. SUMO: a multiface-ted modifier of chromatin structure and function. Dev Cell 2013; 24:1-12; PMID:23328396; http://dx.doi.org/10.1016/j.devcel.2012.11.020
52. Kamitani T, Kito K, Nguyen HP, Wada H, Fukuda-Kamitani T, Yeh ETH. Identification of three major sentrinization sites in PML. J Biol Chem 1998; 273:26675-82; PMID:9756909; http://dx.doi.org/10.1074/jbc.273.41.26675
53. Sternsdorf T, Jensen K, Will H. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol 1997; 139:1621-34; PMID:9412458; http://dx.doi.org/10.1083/jcb.139.7.1621
54. Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998; 17:61-70; PMID:9427741; http://dx.doi.org/10.1093/emboj/17.1.61
55. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. The mechanisms of PML-nuclear body formation. Mol Cell 2006; 24:331-9; PMID:17081985; http://dx.doi.org/10.1016/j.molcel.2006.09.013
56. Matunis MJ, Zhang XD, Ellis NA. SUMO: the glue thatbinds. Dev Cell 2006; 11:596-7; PMID:17084352; http://dx.doi.org/10.1016/j.devcel.2006.10.011
57. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, de Thee H. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008; 10:547-55; PMID:18408733; http://dx.doi.org/10.1038/ncb1717
58. Zhu J, Zhou J, Peres L, Riaucoux F, Honore N, Kogan S, de Thee H. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 2005; 7:143-53; PMID:15710327; http://dx.doi.org/10.1016/j.ccr.2005.01.005
59. Lin DY, Huang YS, Jeng JC, Kuo HY, Chang CC, Chao TT, Ho CC, Chen YC, Lin TP, Fang HI. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 2006; 24:341-54; PMID:17081986; http://dx.doi.org/10.1016/j.molcel.2006.10.019
60. Weger S, Hammer E, Engstler M. The DNA topo-isomerase I binding protein topors as a novel cellular target for SUMO-1 modification: characterization of domains necessary for subcellular localization and sumolation. Exp Cell Res 2003; 290:13-27; PMID:14516784; http://dx.doi.org/10.1016/S0014-4827(03)00292-1
61. Sung KS, Lee YA, Kim ET, Lee SR, Ahn JH, Choi CY. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53. Exp Cell Res 2011; 317:1060-70; PMID:21192925; http://dx.doi.org/10.1016/j.yexcr.2010.12.016
62. Duprez E, Saurin AJ, Desterro JM, Lallemand-Brei-tenbach V, Howe K, Boddy MN, Solomon E, de Thee H, Hay RT, Freemont PS. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci 1999; 112:381-93; PMID:9885291
63. Schmitz ML, Grishina I. Regulation of the tumor suppressor PML by sequential post-translational modifications. Front Oncol 2012; 2:204; PMID:23293771; http://dx.doi.org/10.3389/fonc.2012.00204
64. Wolyniec K, Carney DA, Haupt S, Haupt Y. Newstrat-egies to direct therapeutic targeting of PML to treat cancers. Front Oncol 2013; 3:124; PMID:23730625; http://dx.doi.org/10.3389/fonc.2013.00124
65. Cheng X, Kao HY. Post-translational modifications of PML: consequences and implications. Front Oncol 2012; 2:210; PMID:23316480
66. Gresko E, Ritterhoff S, Sevilla-Perez J, Roscic A, Frobius K, Kotevic I, Vichalkovski A, Hess D, Hemmings BA, Schmitz ML. PML tumor suppressor is regulated by HIPK2-mediated phosphoryla-tion in response to DNA damage. Oncogene 2009; 28:698-708; PMID:19015637; http://dx.doi.org/10.1038/onc.2008.420
67. Yang S, Kuo C, Bisi JE, Kim MK. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 2002; 4:865-70; PMID:12402044; http://dx.doi.org/10.1038/ncb869
68. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 2004; 6:665-72; PMID:15195100; http://dx.doi.org/10.1038/ncb1147
69. Hayakawa F, Privalsky ML. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 2004; 5:389-401; PMID:15093545; http://dx.doi.org/10.1016/S1535-6108(04)00082-0
70. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B, Teruya-Feldstein J, Tempst P, Pandolfi PP. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 2006; 126:269-83; PMID:16873060; http://dx.doi.org/10.1016/j.cell.2006.05.041
71. Hecker CM, Rabiller M, Haglund K, Bayer P, Dikic I. Specification of SUMO1- and SUMO2- interacting Motifs. J Biol Chem 2006; 281:16117-27; PMID:16524884; http://dx.doi.org/10.1074/jbc.M512757200
72. Hayakawa F, Abe A, Kitabayashi I, Pandolfi PP, Naoe T. Acetylation of PML is involved in histone deacety-lase inhibitor-mediated apoptosis. J Biol Chem 2008; 283:24420-5; PMID:18621739; http://dx.doi.org/10.1074/jbc.M802217200
73. Ullmann R, Chien CD, Avantaggiati ML, Muller S. An acetylation switch regulates SUMO-dependent protein interaction networks. Mol Cell 2012; 46:759-70; PMID:22578841; http://dx.doi.org/10.1016/j. molcel.2012.04.006
74. Dellaire G, Ching RW, Ahmed K, Jalali F, Tse KC, Bristow RG, Bazett-Jones DP. Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J Cell Biol 2006; 175:55-66; PMID:17030982; http://dx.doi.org/10.1083/jcb.200604009
75. Quimby BB, Yong-Gonzalez V, Anan T, Strunnikov AV, Dasso M. The promyelocytic leukemia protein stimulates SUMO conjugation in yeast. Oncogene 2006; 25:2999-3005; PMID:16501610; http://dx.doi.org/10.1038/sj.onc.1209335
76. Chu Y, Yang X. SUMOE3ligaseactivityofTRIMpro-teins. Oncogene 2011; 30:1108-16; PMID:20972456; http://dx.doi.org/10.1038/onc.2010.462
77. Cuchet D, Sykes A, Nicolas A, Orr A, Murray J, Sirma H, Heeren J, Bartelt A, Everett RD. PML iso-forms I and II participate in PML-dependent restriction of HSV-1 replication. J Cell Sci 2011; 124:280-91; PMID:21172801; http://dx.doi.org/10.1242/jcs.075390
78. Cho EJ, Kim JS. Crowding effects on the formation and maintenance of nuclear bodies: insights from molecular-dynamics simulations of simple spherical model par-ticles. Biophys J 2012; 103:424-33; PMID:22947858; http://dx.doi.org/10.1016/j.bpj.2012.07.007
79. Bossis G, Melchior F. Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes. Mol Cell 2006; 21:349-57; PMID:16455490; http://dx.doi.org/10.1016/j.molcel.2005.12.019
80. Xu Z, Chan HY, Lam WL, Lam KH, Lam LS, Ng TB, Au SW. SUMO proteases: redox regulation and biological consequences. Antioxidants Redox Signal 2009; 11:1453-84; PMID:19186998; http://dx.doi.org/10.1089/ars.2008.2182
81. Mukhopadhyay D, Dasso M. Modification in reverse: the SUMO proteases. Trends Biochem Sci 2007; 32:286-95; PMID:17499995; http://dx.doi.org/10.1016/j.tibs.2007.05.002
82. Kroemer G, de Thee H. Arsenic trioxide, a novel mito-chondriotoxic anti-cancer agent? J Natl Cancer Inst 1999; 91:743-5; PMID:10328097; http://dx.doi.org/10.1093/jnci/91.9.743
83. Kawata K, Yokoo H, Shimazaki R, Okabe S. Classification of heavy-metal toxicity by human DNA micro-array analysis. Environ Sci Technol 2007; 41:3769-74; PMID:17547211; http://dx.doi.org/10.1021/es062717d
84. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thir-ugnanam R, Abraham A, Shaji RV. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010; 28:3866-71; PMID:20644086; http://dx.doi.org/10.1200/JCO.2010.28.5031
85. Negorev D, Maul GG. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 2001; 20:7234-42; PMID:11704851; http://dx.doi.org/10.1038/sj.onc.1204764
86. Lindsay CR, Morozov VM, Ishov AM. PML NBs (ND10) and Daxx: from nuclear structure to protein function. Front Biosci 2008; 13:7132-42; PMID:18508722; http://dx.doi.org/10.2741/3216
87. Psakhye I, Jentsch S. Protein group modification and synergy in the SUMO pathway as exemplified in DNA repair. Cell 2012; 151:807-20; PMID:23122649; http://dx.doi.org/10.1016/j.cell.2012.10.021
88. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008; 10:538-46; PMID:18408734; http://dx.doi.org/10.1038/ncb1716
89. Moller A, Sirma H, Hofmann TG, Rueffer S, Klimc-zak E, Droge W, Will H, Schmitz ML. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 2003; 63:4310-4; PMID:12907596
90. Guo L, Giasson BI, Glavis-Bloom A, Brewer MD, Shorter J, Gitler AD, Yang X. A cellular system that degrades misfolded proteins and protects against neurodegeneration. Mol Cell 2014; 55:15-30; PMID: 24882209; http://dx.doi.org/10.1016/j.molcel.2014. 04.030
91. Geoffroy MC, Hay RT. An additional role for SUMO in ubiquitin-mediated proteolysis. Nat Rev Mol Cell Biol 2009; PMID:19474794
92. Saitoh H, Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 2000; 275:6252-8; PMID:10692421; http://dx.doi.org/10.1074/jbc.275.9. 6252
93. Tammsalu T, Matic I, Jaffray EG, Ibrahim AF, Tatham MH, Hay RT. Proteome-wide identification of SUMO2 modification sites. Sci Signal 2014; 7:rs2; PMID:24782567; http://dx.doi.org/10.1126/scisignal. 2005146
94. Kuo D, Nie M, Courey AJ. SUMO as a solubility tag and in vivo cleavage of SUMO fusion proteins with Ulp1. Methods Mol Biol 2014; 1177:71-80; PMID:24943315; http://dx.doi.org/10.1007/978-1-4939-1034-2_6
95. Krumova P, Weishaupt JH. Sumoylation in neurode-generative diseases. Cell Mol Life Sci 2013; 70:2123-38; PMID:23007842; http://dx.doi.org/10.1007/s00018-012-1158-3
96. Marblestone JG, Edavettal SC, Lim Y, Lim P, Zuo X, Butt TR. Comparison of SUMO fusion technology with traditional gene fusion systems: enhanced expression and solubility with SUMO. Protein Sci 2006; 15:182-9; PMID:16322573; http://dx.doi.org/10.1110/ps.051812706
97. Fabunmi RP, Wigley WC, Thomas PJ, DeMartino GN. Interferon gamma regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies. J Cell Sci 2001; 114:29-36; PMID:11112687
98. Gartner A, Muller S. PML, SUMO, and RNF4: Guardians of Nuclear Protein Quality. Mol Cell 2014; 55:1-3; PMID:24996060; http://dx.doi.org/10.1016/j.molcel.2014.06.022
99. Golebiowski F, Matic I, Tatham MH, Cole C, Yin Y, Nakamura A, Cox J, Barton GJ, Mann M, Hay RT. System-wide changes to SUMO modifications in response to heat shock. Sci Signal 2009; 2:ra24; PMID: 19471022; http://dx.doi.org/10.1126/scisignal.2000282
100. Tatham MH, Matic I, Mann M, Hay RT. Comparative proteomic analysis identifies a role for SUMO in protein quality control. Sci Signal 2011; 4:rs4; PMID: 21693764; http://dx.doi.org/10.1126/scisignal.2001484
101. Morris JR. SUMO in the mammalian response to DNA damage. Biochem Soc Trans 2010; 38:92-7; PMID:20074042; http://dx.doi.org/10.1042/BST0380092
102. Morris JR, Boutell C, Keppler M, Densham R, Weekes D, Alamshah A, Butler L, Galanty Y, Pangon L, Kiuchi T, et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009; 462:886-90; PMID:20016594; http://dx.doi.org/10.1038/nature08593
103. Jana NR, Nukina N. Recent advances in understanding the pathogenesis of polyglutamine diseases: involvement of molecular chaperones and ubiquitin-proteasome pathway. J Chem Neuroanat 2003; 26:95-101; PMID:14599658; http://dx.doi.org/10.1016/S0891-0618(03)00029-2
104. Korb E, Finkbeiner S. PML in the brain: from development to degeneration. Front Oncol 2013; 3:242; PMID:24062991; http://dx.doi.org/10.3389/fonc.2013. 00242
105. Salomoni P, Betts-Henderson J. The role of PML in the nervous system. Mol Neurobiol 2011; 43:114-23; PMID:21161613; http://dx.doi.org/10.1007/s12035-010-8156-y
106. Takahashi J, Fujigasaki H, Iwabuchi K, Bruni AC, Uchihara T, El Hachimi KH, Stevanin G, Diirr A, Lebre AS, Trottier Y, et al. PML nuclear bodies and neuronal intranuclear inclusion in polyglutamine diseases. Neurobiol Dis 2003; 13:230-7; PMID:12901837; http://dx.doi.org/10.1016/S0969-9961(03)00080-9
107. Stadler M, Chelbi-Alix MK, Koken MHM, Venturini L, Lee C, Saib A, Quignon F, Pelicano L, Guillemin MC, Schindler C, et al. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 1995; 11:2565-73; PMID:8545113
108. Everett RD, Parada C, Gripon P, Sirma H, Orr A. Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J Virol 2008; 82:2661-72; PMID:18160441; http://dx.doi.org/10.1128/JVI.02308-07
109. Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de The H, Chelbi-Alix MK. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J 2001; 20:3495-505; PMID:11432836; http://dx.doi.org/10.1093/emboj/20.13.3495
110. Zhu J, Koken MHM, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de Thee H. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997; 94:3978-83; PMID:9108090; http://dx.doi.org/10.1073/pnas.94.8.3978
111. Quignon F, de Bels F, Koken M, Feunteun J, Ameisen J-C, de Thee H. PML induces a caspase-inde-pendent cell death process. Nat Genet 1998; 20:259-65; PMID:9806544; http://dx.doi.org/10.1038/3068
112. Sahin U, Ferhi O, Carnec X, Zamborlini A, Peres L, Jollivet F, Vitaliano-Prunier A, de Thee H, Lallemand-Breitenbach V. Interferon controls SUMO availability via the Lin28 and let-7 axis to impede virus replication. Nat Commun 2014; 5:4187; PMID:24942926; http://dx.doi.org/10.1038/ncomms5187
113. Guldner H, Szostecki C, Grotzinger T, Will H. IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. J Immunol 1992; 149:4067-73; PMID:1281200
114. Kyratsous CA, Silverstein SJ. Components of nuclear domain 10 bodies regulate varicella-zoster virus replication. J Virol 2009; 83:4262-74; PMID:19211749; http://dx.doi.org/10.1128/JVI.00021-09
115. Chee AV, Lopez P, Pandolfi PP, Roizman B. Promye-locytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J Virol 2003; 77:7101-5; PMID:12768029; http://dx.doi.org/10.1128/JVI.77.12.7101-7105.2003
116. Everett RD, Rechter S, Papior P, Tavalai N, Stam-minger T, Orr A. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J Virol 2006; 80:7995-8005; PMID:16873256; http://dx.doi.org/10.1128/JVI.00734-06
117. Ribet D, Cossart P. Pathogen-mediated posttransla-tional modifications: A re-emerging field. Cell 2010; 143:694-702; PMID:21111231; http://dx.doi.org/10.1016/j.cell.2010.11.019
118. Ribet D, Hamon M, Gouin E, Nahori MA, Impens F, Neyret-Kahn H, Gevaert K, Vandekerckhove J, Dejean A, Cossart P. Listeria monocytogenes impairs SUMOylation for efficient infection. Nature 2010; 464:1192-5; PMID:20414307; http://dx.doi.org/10.1038/nature08963
119. Everett RD, Boutell C, Hale BG. Interplay between viruses and host sumoylation pathways. Nat Rev Microbial 2013; 11:400-11; PMID:23624814; http://dx.doi.org/10.1038/nrmicro3015
120. Boutell C, Sadis S, Everett RD. Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro. J Virol 2002; 76:841-50; PMID:11752173; http://dx.doi.org/10.1128/JVI.76.2.841-850.2002
121. El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de Thee H, Bazarbachi A. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000; 96:2849-55; PMID: 11023521
122. El Hajj H, El-Sabban M, Hasegawa H, Zaatari G, Ablain J, Saab ST, Janin A, Mahfouz R, Nasr R, Kfoury Y, et al. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med 2010; 207:2785-92; PMID:21135137; http://dx.doi.org/10.1084/jem.20101095
123. Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H, et al. Phase 2 study of the efficacy and safety of the combination of arsenic triox-ide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009; 113:6528-32; PMID:19411628; http://dx.doi.org/10.1182/blood-2009-03-211821
124. Janer A, Martin E, Muriel MP, Latouche M, Fujiga-saki H, Ruberg M, Brice A, Trottier Y, Sittler A. PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins. J Cell Biol 2006; 174:65-76; PMID:16818720; http://dx.doi.org/10.1083/jcb.200511045
125. Chort A, Alves S, Marinello M, Dufresnois B, Dorn-bierer JG, Tesson C, Latouche M, Baker DP, Barkats M, El Hachimi KH, et al. Interferon beta induces clearance of mutant ataxin 7 and improves locomotion in SCA7 knock-in mice. Brain 2013; 136:1732-45; PMID:23518714; http://dx.doi.org/10.1093/brain/awt061
126. Janer A, Werner A, Takahashi-Fujigasaki J, Daret A, Fujigasaki H, Takada K, Duyckaerts C, Brice A, Dejean A, Sittler A SUMOylation attenuates the aggregation propensity and cellular toxicity of the pol-yglutamine expanded ataxin-7. Hum Mol Gen 2010; 19:181-95; PMID:19843541; http://dx.doi.org/10.1093/hmg/ddp478
127. Gottifredi V, Prives C. P53 and PML: new partners in tumor suppression. Trends Cell Biol 2001; 11:184-7; PMID:11316590; http://dx.doi.org/10.1016/S0962-8924(01)01983-3
128. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 2000; 14:2015-27; PMID:10950866
129. Janderova-Rossmeislova L, Novakova Z, Vlasakova J, Philimonenko V, Hozak P, Hodny Z. PML protein association with specific nucleolar structures differs in normal, tumor and senescent human cells. J Struct Biol 2007; 159:56-70; PMID:17428679; http://dx.doi.org/10.1016/j.jsb.2007.02.008
130. Vernier M, Bourdeau V, Gaumont-Leclerc MF, Moi-seeva O, Begin V, Saad F, Mes-Masson AM, Ferbeyre G. Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev 2011; 25:41-50; PMID:21205865; http://dx.doi.org/10.1101/gad.1975111
131. Marcos-Villar L, Perez-Giron JV, Vilas JM, Soto A, de la Cruz-Hererra CF, Lang V, Collado M, Vidal A, Rodriguez MS, Munoz-Fontela C, et al. SUMOyla-tion of p53 mediates interferon activities. Cell Cycle 2013; 12:2809-16; PMID:23966171; http://dx.doi.org/10.4161/cc.25868
132. Chiantore MV, Vannucchi S, Accardi R, Tommasino M, Percario ZA, Vaccari G, Affabris E, Fiorucci G, Romeo G. Interferon-beta induces cellular senescence in cutaneous human papilloma virus-transformed human keratinocytes by affecting p53 transactivating activity. PloSOne 2012;7:e36909; PMID:22615843; http://dx.doi.org/10.1371/journal.pone.0036909
133. Okazaki T, Kageji T, Kuwayama K, Kitazato KT, Mure H, Hara K, Morigaki R, Mizobuchi Y, Matsuzaki K, Nagahiro S. Up-regulation of endogenous PML induced by a combination of interferon-β and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma. Cancer Lett 2012; 323:199-207; PMID:22542810; http://dx.doi.org/10.1016/j.canlet.2012.04.013
134. Hubackova S, Novakova Z, Krejcikova K, Kosar M, Dobrovolna J, Duskova P, Hanzlikova H, Vancurova M, Barath P, Bartek J, et al. Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling. Cell Cycle 2010; 9:3085-99; PMID:20699642; http://dx.doi.org/10.4161/cc.9.15.12521
135. Liu JH, Liu CC, Yen CC, Gau JP, Wang WS, Tzeng CH. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells. Int J Cancer 2009; 125:71-7; PMID:19291793; http://dx.doi.org/10.1002/ijc.24329
136. Kim TK, Lee JS, Oh SY, Jin X, Choi YJ, Lee TH, Lee Eh, Choi YK, You S, Chung YG, et al. Direct tran-scriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells. Cancer Res 2007; 67:11133-40; PMID:18056437; http://dx.doi.org/10.1158/0008-5472.CAN-07-1342
137. Muromoto R, Ishida M, Sugiyama K, Sekine Y, Oritani K, Shimoda K, Matsuda T. Sumoylation of Daxx regulates IFN-induced growth suppression of B lymphocytes and the hormone receptor-mediated transactivation. J Immunol 2006; 177:1160-70; PMID:16818774; http://dx.doi.org/10.4049/jimmunol.177.2.1160